新生血管性年龄相关性黄斑变性患者对雷珠单抗港式给药系统与玻璃体内注射的偏好和治疗满意度:一项随机临床试验
Archway 3期随机开放标签试验在美国78个中心纳入418例新生血管性年龄相关性黄斑变性患者,按3:2随机接受雷珠单抗港式给药系统(PDS,100 mg/mL,每24周固定补充更换)或玻璃体内雷珠单抗注射(0.5 mg,每4周)。第40周时两组治疗满意度总分差异极小(PDS组均值68.0 vs 注射组66.1,差值1.9);PDS组234例中218例(93.2%)偏好PDS而非既往玻璃体内注射。
要点
- 第40周PDS组与玻璃体内注射组治疗满意度总分均值分别为68.0与66.1,差值1.9(95%CI 0.7-3.1)。
- PDS组234例中218例(93.2%)偏好PDS,3例(1.3%)偏好既往玻璃体内注射,172例(73.5%)非常强烈偏好PDS。
- 同时接受对侧眼注射的78例中72例(92.3%)偏好PDS。
核心结论
- 尽管PDS组几乎所有患者偏好PDS而非既往玻璃体内注射,但两种给药方式均有较高的治疗满意度。
- 这些发现为PDS作为新生血管性年龄相关性黄斑变性患者有意义的替代治疗选择提供了进一步证据。
研究设计与样本
- Archway为在美国78个中心开展的3期随机活性对照开放标签临床试验,研究时间为2019年9月12日至2020年5月22日主要读数。
- 纳入50岁及以上、筛查前9个月内诊断新生血管性年龄相关性黄斑变性且有抗血管内皮生长因子治疗应答记录的患者;619例筛查中418例入组,415例纳入主要分析,234例纳入次要探索性分析。
- 患者按3:2随机接受雷珠单抗PDS(100 mg/mL,每24周固定补充更换)或玻璃体内雷珠单抗注射(0.5 mg,每4周)。
主要发现
- 基线平均(SD)年龄为75.0(7.9)岁;234例(59%)为女性,162例(41%)为男性。
- 第40周PDS组与玻璃体内注射组总体治疗满意度评分差异极小(均值68.0,95%CI 67.4-68.6,n=237 vs 均值66.1,95%CI 64.9-67.3,n=159;差值1.9,95%CI 0.7-3.1)。
- PDS组248例中234例(94.4%)纳入PPPQ分析;第40周PDS组234例中218例(93.2%)偏好PDS治疗,3例(1.3%)偏好既往玻璃体内注射,172例(73.5%)非常强烈偏好PDS。
- 同时接受对侧眼注射的患者(n=78)中72例(92.3%)偏好PDS。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The port delivery system (PDS) with ranibizumab has demonstrated noninferior and equivalent efficacy compared with monthly intravitreal injections of ranibizumab, an anti-vascular endothelial growth factor (VEGF) agent, in patients with neovascular age-related macular degeneration (nAMD), but evaluating patient preference is important to help inform clinical decision-making. OBJECTIVE: Evaluate treatment satisfaction for ranibizumab delivered via PDS vs intravitreal injections as well as patient preference among those assigned to PDS. DESIGN, SETTING, AND PARTICIPANTS: Archway was a phase 3 randomized active-comparator open-label clinical trial conducted at 78 sites in the US. Patients 50 years and older with nAMD diagnosed within 9 months of screening with a documented response to anti-VEGF therapy were included. Of 619 patients screened, 418 were enrolled; 415 were included in the primary analysis and 234 were included in the secondary exploratory analysis. The Archway study ran from September 12, 2019, through primary readout on May 22, 2020. INTERVENTIONS: Patients were randomized 3:2 to PDS with ranibizumab, 100 mg/mL, with fixed refill exchanges every 24 weeks or intravitreal ranibizumab injections, 0.5 mg, every 4 weeks. MAIN OUTCOMES AND MEASURES: Treatment satisfaction was measured using the Macular Disease Treatment Satisfaction Questionnaire in the PDS and intravitreal injection arms at week 40. Patient preference was assessed using the content-validated PDS Patient Preference Questionnaire (PPPQ), which measured the proportion of patients in the PDS arm with monthly monitoring who preferred treatment with the PDS at week 40 over previous intravitreal injections or concurrent fellow-eye injections. Both outcomes were exploratory end points. RESULTS: The mean (SD) age of participants at baseline was 75.0 (7.9) years; 234 participants (59%) were women and 162 (41%) were men. At week 40, differences in overall treatment satisfaction scores were minimal for the PDS and intravitreal injection arms (mean, 68.0; 95% CI, 67.4-68.6; n = 237 and mean, 66.1; 95% CI, 64.9-67.3; n = 159, respectively; difference, 1.9; 95% CI, 0.7-3.1). A total of 234 of 248 patients (94.4%) in the PDS arm were included in the PPPQ analysis. At week 40, almost all patients in the PDS arm preferred treatment via PDS (218 of 234 [93.2%]) vs previous intravitreal injections (3 of 234 [1.3%]), including 172 of 234 (73.5%) with a very strong preference for the PDS. In patients who received concurrent fellow-eye injections (n = 78), 72 (92.3%) preferred the PDS. CONCLUSIONS AND RELEVANCE: Although PDS treatment was preferred by almost all patients assigned to PDS over previous intravitreal injections, both delivery methods have high treatment satisfaction. These findings provide further evidence for the PDS as a meaningful alternative treatment option for patients with nAMD. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03677934.
引用
- Chang MA, Kapre A, Kaufman D, et al. Patient Preference and Treatment Satisfaction With a Port Delivery System for Ranibizumab vs Intravitreal Injections in Patients With Neovascular Age-Related Macular Degeneration: A Randomized Clinical Trial. JAMA Ophthalmol. 2022. PMID: 35708706. doi:10.1001/jamaophthalmol.2022.1091
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。